

**Minutes of the March 8, 2013
Pharmacy & Therapeutics (P&T) Committee Meeting
SD Department of Social Services, Medical Services Division**

Members present

Debra Farver, PharmD; Timothy Soundy, MD; Bill Ladwig, RPh; Mikel Holland, MD; Kelly Oehlke, PharmD; Lenny Petrick, PharmD; Dana Darger, RPh; James Engelbrecht, MD

Members absent

Rick Holm, MD; Michelle Baack, MD

DSS staff present

Mike Jockheck, RPh; Ann Schwartz, Dep. Director of Medical Services; Kirby Stone, Director of Medical Services

HID staff present

Candace Rieth, PharmD

Administrative Business

The P&T meeting was called to order by D. Darger at approximately 1:00pm. The minutes of the December 14, 2012 meeting were presented. D. Farver made a motion to approve. K. Oehlke seconded the motion. The motion was approved unanimously.

Prior Authorization Update and Statistics

C. Rieth presented an overview of the prior authorization (PA) activity for January 2013. There were a total of 3,198 PAs processed in the month of January, with 98.91% of those requests responded to in less than 8 hours. There were 2,527 (79%) requests received electronically and 671 (21%) requests received by fax.

Analysis of the Top 15 Therapeutic Classes

C. Rieth reviewed the Top 15 Therapeutic Classes by total cost of claims from 10/01/2012 – 12/31/2012. The top five classes were antipsychotics, respiratory and CNS stimulants, amphetamines, central nervous system agents misc., and corticosteroids (respiratory tract). The top 15 therapeutic classes make up 37.69% of total claims. C. Rieth also reviewed the top 25 drugs based on total claims cost and number of claims. The top 25 drugs by claims cost make up 13.20% of total claims. After reviewing the reports, the committee requested that PPIs be discussed at the next meeting.

Genitourinary Smooth Muscle Relaxants Second Review

C. Rieth reviewed genitourinary smooth muscle relaxant (GSM) clinical information and utilization at the December meeting and a motion was made and approved to develop a prior authorization form and criteria. The committee reviewed the form and criteria presented. There was no public comment. A motion was made by B. Ladwig to approve the GSM form and criteria. D. Farver seconded the motion. The motion was approved.

Xeljanz Review

C. Rieth reviewed Xeljanz clinical information at the December meeting and a motion was made and approved to develop a prior authorization form and criteria. The committee reviewed the form and criteria presented. There was no public comment. A motion was made by J. Engelbrecht to approve the Xeljanz form and criteria. T. Soundy seconded the motion. The motion was approved.

Prior Authorization Forms and Criteria Annual Review

C. Rieth reviewed all of the current prior authorization forms and criteria. Changes made include:

1. Ambien CR-bring back a review on the sedative/hypnotic class including the new dosing guidelines based on gender.
2. Head Lice Medication-add agents that require prior authorization to the form.
3. Targeted Immunomodulators-change the form name to DMARDs

B. Ladwig made a motion to make the listed changes to the prior authorization forms. J. Englebrecht seconded the motion. The motion was approved.

Medications used to treat ADHD Review

C. Rieth reviewed agents used to treat ADHD clinical information and utilization. A suggestion was made to refer this topic to the DUR committee. The P&T committee agreed to table the ADHD topic, at this time.

Juxtapid Review

C. Rieth reviewed Juxtapid clinical information. The P&T committee tabled this topic.

Gattex Review

C. Rieth reviewed Gattex clinical information. The P&T committee requested that Gattex be reviewed in one year.

Opiates Review

C. Rieth reviewed opiate clinical information and utilization. The P&T committee requested more data be provided at the June meeting.

The next meeting date is scheduled for June 28, 2013. A motion was made by D. Farver to adjourn the SD Medicaid P&T meeting. K. Oehlke seconded the motion. Motion passed unanimously and the meeting was adjourned.